Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

HSE drugs group recommends intranasal naloxone be added to drugs scheme

By Mindo - 03rd Dec 2020 | 32 views

The HSE drugs group has recommended that intranasal naloxone be included under the community drugs schemes for GPs, the Medical Independent has learned. The HSE’s executive management team (EMT) is considering this recommendation.

At the HSE drugs group meeting in June, it was “unanimously recommended that intranasal naloxone should be included under the community drugs schemes for GPs designated as level one and level two opioid substitution treatment prescribers to be able to prescribe this medicine for storage and administration in the home in the event of the accidental overdose of opioids”.

According to meeting minutes, the group recognised that drug-related mortality rates in Ireland are among the highest in the EU and welcomed the expansion of naloxone services in that context.

“The group were assured that HSE addiction services were supportive of this product being available under the scheme. The overall drug budget impact presented was considered to be relatively modest.”

Intranasal naloxone is currently available through the HSE naloxone demonstration project. Up until the end of July, the HSE provided 1,601 packs of Prenoxad (injectable naloxone) and 1,700 packs of Nyxoid (intranasal naloxone).

Leave a Reply

Latest Issue
The Medical Independent 9th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read